Accès ouvert
2022
article
OpenAlex
Brian C. Avanzino, Kirthana Prabhakar, Pranjali Dalvi, Sharon Hartstein et autres
The use of T-cell engagers (TCEs) to treat solid tumors is challenging, and several have been limited by narrow therapeutic windows due to substantial on-target, off-tumor toxicities due to the expression of low levels of target antigens on healthy tissues. Here, we …
us
(code pays fourni par la source)
2022
conference-abstract
OpenAlex
Brian C. Avanzino, Kirthana Prabhakar, Pranjali Dalvi, Sharon Hartstein et autres
Abstract The use of T cell engagers (TCEs) to treat solid tumors in humans is challenging, and several have been limited by narrow therapeutic windows due to substantial toxicity. Dose-limiting toxicities of TCEs include cytokine release syndrome (CRS) and on-target, off-tumor toxicities …
us
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Katherine E. Harris, Kyle J. Lorentsen, Harbani K. Malik-Chaudhry, Kaitlyn Loughlin et autres
The use of recombinant interleukin-2 (IL-2) as a therapeutic protein has been limited by significant toxicities despite its demonstrated ability to induce durable tumor-regression in cancer patients. The adverse events and limited efficacy of IL-2 treatment are due to the preferential binding …
fr
(code pays fourni par la source)
2020
conference-abstract
OpenAlex
Ben D. Buelow, Brian C. Avanzino, Aarti Balasubramani, Andrew A. Boudreau et autres
e18050 Background: Ovarian Cancer (OvCa) is the leading cause of gynecologic cancer mortality in women. Since the introduction of platinum-based chemotherapy there has been little change in the prognosis of OvCa patients, with < 30% overall survival in advanced disease, creating an …
us
(code pays fourni par la source)